After Aclara Purchase, ViroLogic Hopes HIV Dx Past Will Drive Success in Cancer | GenomeWeb

With a hungry eye on the cancer diagnostics market, ViroLogic has finally closed its $180 million acquisition of Aclara Biosciences, whose eTag technology may allow the combined company to create products complementing targeted-medicine hopefuls Erbitux and Iressa, among other cancer drugs.

Since some physicians are familiar with ViroLogic’s molecular diagnostics for HIV drug resistance, the company hopes its success in this market can act as a springboard into cancer testing and treatment, ViroLogic CEO Bill Young told Pharmacogenomics Reporter.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.